The impact of different types of stents on clinical outcomes is of great interest because coronary disease is a major cause of morbidity and mortality for both genders. This study aimed to conduct a risk-adjusted gender-based analysis of clinical outcomes following drug-eluting stent (DES) versus bare metal stent (BMS) implantation in patients with coronary artery disease. Methods: We compared risk-adjusted total mortality rate, myocardial infarction, and event-free survival in a consecutive cohort of 7,662 patients undergoing percutaneous coronary intervention at our institution, including 1835 (25.4%) women. Follow-up was 6 months to 6.2 years (mean 3.5 years, median 3.6 years). Results: Women were older than men and more likely to suffer from diabetes, hypertension, or congestive heart failure. Smokers were more often men, and men were more likely to have had prior coronary bypass surgery compared to women. A DES was used in 39.9% of males and 39.5% of females. Both genders derived a significant long-term clinical benefit from DESs compared to BMSs; advantages were observed for mortality (men: HR=0.78, 95% CI: 0.64 -0.96, p=0.016; women: HR=0.62, 95% CI: 0.45 -0.85, p=0.003) and major adverse cardiac events (men: HR=0.73, 95% CI: 0.63-0.84, p<0.001; women: HR=0.76, 95% CI: 0.52-0.84, p=0.001). Among BMStreated patients, women had worse cumulative clinical outcomes than men. DESs eliminated the gender differences in cardiac prognosis. Conclusion: Our analysis indicated a profound prognostic advantage for DESs versus BMSs among both genders, though female patients appeared to derive the greatest benefit.
TCT-205 The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions
Ted Spase Trajceski, Lulzim Brovina, Zivko Petrovski, Blerim Zuna, Borce Petrovski Spitali Zemres, Prishtina, Albania Background: We compared the safety and efficacy of different permanent polymer based drug-eluting stents (PBS) with a polymer-free drug-eluting stent (PFS-Yukon). In unselected real-world patients with coronary lesions of various complexities, we retrospectively compared both stent designs. Methods: A total of 617 lesions in patients with symptomatic CAD were treated with PBS (n = 383) or with PFS (n = 234). The PBS group consisted of 44(12%) Cypher, 101(26%) Xience, 107(28%) Endeavor, 55(14%) Infinium and 75(20%) Coroflex Please stents, assigned to patients and lesions by shelf disposal and target vessel dimensions. The primary clinical endpoint of this study was a composite of cardiac death, myocardial infarction and clinical-indicated target vessel revascularisation (MACE). Results: Follow-up was obtained in 98,2% of patients. All patients were treated with clopidrogrel and aspirin during follow up. Polymer free stents were non-inferior to polymer-stents for the primary endpoint at 9 months (13 [5.6%] .29) were similar for both stent types. Analysis of MACE after 9 months resulted in 4 (1.7%) definitive stent thrombosis causing MI in PFS vs. 18(4.7%) in PBS treated lesions, with borderline significant difference (log rank, p=0.052). In the cox proportional regression analysis of MACE, none of the stents showed different survival according to stratification by presence of Diabetes, ST-elevationMI, multivessel disease, Left anterior, long or small vessel lesions, (p=0.93; p=0.97; p=0.99; p=0.95; p=0.96; p=0.85), respectively. Conclusion: Up to 9 months after PCI of real-world coronary lesions, there were no statistically significant differences in MACE between lesions treated with the polymerfree YUKON stent and the group of polymer-based stents.
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Real-World Comparison Of Clinical Outcomes Of Patients Who Received New Generation Platinum Chromium Everolimus-Eluting Stent Versus Cobalt Chromium Everolimus-Eluting Stent
Ruogu Li, Adrian F Low, Chi Hang Lee, Mark Chan, Swee Guan Teo, Koo Hui Chan, Arthur Mark Richards, Huay Cheem Tan cardiac, National University Heart Centre, Singapore, Singapore Background: The safety and efficacy of the first generation cobalt chromium everolimus-eluting stent (EES) have been demonstrated in several trials. The PROMUS Element (Boston Scientific, Natick, Massachusetts) stent is a new generation EES, made of platinum chromium alloy with thin strut designed to improve radial strength, radiopacity, vessel conformability, fracture resistance, side-branch access and deliverability. We aim to compare the safety and efficacy of this novel PtCr-EES with the first generation cobalt chromium EES (CoCr-EES) in patients who received them.
Methods:
We analyzed retrospectively 805 patients who received PtCr-EES(n=391) or CoCr-EES (n=414) from our centre cardiovascular database. The primary endpoint was the 6-month composite major adverse cardiac events (MACE) that include cardiac death, myocardial infarction, target vessel revascularization and stent thrombosis. Results: The mean age of the cohort was 58.7±10.1 years with males constituting 82.7%. Diabetes mellitus was present in 322 (40.0%) patients. The majority (63.1%) of the lesions treated were of AHA/ACC Type B2/C. The mean lesion length in the 2 groups were 26.14±12.19 mm (PtCr-EES) vs 24.14±11.86 (CoCr-EES), p=0.009 respectively; and the stent length were 31.27±14.38mm (PtCr-EES) vs 31.23±14.61mm (CoCr-EES), p=0.96 respectively. At 6 months, the results were as follow: Clinical Outcome Conclusion: Our study showed that PtCr-EES stent, when used in real-world population, showed similar medium-term efficacy as the first generation EES with no safety concerns related to the novel stent material and design. The TVR rate is low at <2% for both groups. Background: Despite the success of percutaneous intervention along with stent deployment in opening up an occluded coronary artery in AMI patients, the phenomenon of distal embolization may result in impaired myocardial perfusion and myocardial recovery and remains a significant concern in reperfusion therapy. The MGUARD TM stent (InspireMD, Tel Aviv, Israel) comprises a mesh which is wrapped around a balloon-expandable, bare metal stent. The mesh is designed to trap thrombus and fragile plaque against the vessel wall and prevent them from entering the lumen thereby preventing distal embolization. The IMOS (International MGUARD Observational Study) Registry enrolled consecutive patients treated with the MGUARD TM stent with the objective to evaluate its clinical performance and safety. Methods: The IMOS registry is a prospective, non-randomized, single arm, multinational, observational study designed to enroll 1000 patients. Angiographic exclusion criteria include heavily calcified lesions and large side branches. The primary endpoint is MACE at 6 months. Patients are evaluated at 1, 6 and 12 months. Results: A total of 382 patients who matched the inclusion/exclusion criteria have been enrolled to date, and were sorted into groups according to clinical presentation and number and type of stent deployed. A group of 203 patients (53.0% of patients enrolled in the registry), who presented with STEMI and in whom only MGUARD TM was implanted, were analyzed and are presented here. 43.6% of these patients suffered from hyperlipidemia, 59.4% from hypertension and 15.3% from diabetes. 8.0% had prior PCI and 9.9% had previous MI. The culprit lesion was in the RCA in 49.7% of cases and in the LAD in 36.2%. A visible thrombus was seen in 98.0%. In 41%, thrombus aspiration was used. Procedure success was 98.0% and final TIMI3 flow was achieved in 93.5% of patients. At 30 days, 6 months and 1 year, MACE rates were 2.4%, 3.2% and 6.0% respectively. Conclusion: PCI with MGUARD TM represents an efficient and safe approach in treating STEMI patients, with low rates of MACE and high rates of procedure and angiographic success.
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